Alessio Cortellini

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Marina Chiara Garassino, Jennifer G. Whisenant, Li‐Ching Huang et al. · The Lancet Oncology · 2020 · 624 citations · Full text

Medicine, Oncology, Clinical Epidemiology +3

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti et al. · Journal for ImmunoTherapy of Cancer · 2019 · 415 citations · Full text

Medicine, Immunology, Oncology +16

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

Alessio Cortellini, Marco Tucci, Vincenzo Adamo et al. · Journal for ImmunoTherapy of Cancer · 2020 · 264 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study

Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida et al. · Hepatology · 2022 · 234 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +11

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

Alessio Cortellini, Sebastiano Buti, Daniele Santini et al. · The Oncologist · 2019 · 221 citations · Full text

Life Sciences, Immunology, Oncology +17